Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) EBT (2019 - 2025)

Historic EBT for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to -$174.1 million.

  • Avidity Biosciences' EBT fell 11712.7% to -$174.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$548.5 million, marking a year-over-year decrease of 9594.62%. This contributed to the annual value of -$322.1 million for FY2024, which is 5218.07% down from last year.
  • As of Q3 2025, Avidity Biosciences' EBT stood at -$174.1 million, which was down 11712.7% from -$156.7 million recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' EBT registered a high of -$23.8 million during Q1 2021, and its lowest value of -$174.1 million during Q3 2025.
  • Moreover, its 5-year median value for EBT was -$52.1 million (2023), whereas its average is -$66.9 million.
  • As far as peak fluctuations go, Avidity Biosciences' EBT tumbled by 29179.95% in 2021, and later plummeted by 257.18% in 2023.
  • Avidity Biosciences' EBT (Quarter) stood at -$38.5 million in 2021, then plummeted by 31.07% to -$50.5 million in 2022, then fell by 19.59% to -$60.3 million in 2023, then tumbled by 69.81% to -$102.5 million in 2024, then plummeted by 69.89% to -$174.1 million in 2025.
  • Its last three reported values are -$174.1 million in Q3 2025, -$156.7 million for Q2 2025, and -$115.3 million during Q1 2025.